Does urinary mycotoxin detection prove the source of exposure or cause of symptoms?

Urinary mycotoxin testing is best understood as exposure biomonitoring, not as a diagnostic test for “mold illness” or a method for identifying a building as the exposure source. This distinction is particularly important when nonspecific symptoms are present.

Clinical interpretation

• A validated urine result documents excretion of a measured mycotoxin, metabolite, or conjugate and therefore supports exposure, usually recent rather than chronic exposure.
• Timing is analyte-specific: urinary deoxynivalenol (DON) may peak about 30–60 minutes after ingestion and is largely eliminated within hours, whereas ochratoxin A (OTA) has more persistent kinetics. For aflatoxin, urinary aflatoxin M1 and aflatoxin-N7-guanine reflect recent exposure, while aflatoxin–albumin in serum reflects longer-term exposure.
• Spot urine concentrations are affected by collection timing and urine dilution; a 24-hour collection better reflects daily excretion but still does not establish clinical harm.

Source attribution and symptoms

• Dietary intake is generally the principal exposure route and can directly produce detectable urinary DON or OTA. Thus, urine testing cannot distinguish food exposure from workplace, outdoor, or indoor sources.
• No validated urinary concentration identifies a specific home or workplace, demonstrates ongoing exposure from a damp building, or predicts disease. CDC does not recommend biologic testing of people in water-damaged buildings for this purpose.
• Detection also cannot establish that the toxin caused symptoms: it does not show a harmful dose, organ injury, temporal dose–response relationship, or exclusion of alternative diagnoses.

Clinical context

• Dampness and indoor mold are associated with respiratory and allergic conditions, but this association does not make a urinary mycotoxin result evidence of individual toxin-mediated illness. Assessment should focus on symptom pattern, moisture/visible damage, and evaluation for conditions such as allergy, asthma, hypersensitivity pneumonitis, or infection when indicated.

Bottom line

• A positive urinary mycotoxin result supports recent exposure/excretion, but alone cannot identify the source, prove ongoing building exposure, or establish that the detected toxin is causing symptoms.